Hospital Universitario Marqués de Valdecilla -ko ikertzaileekin lankidetzan egindako argitalpenak (42)

2024

  1. Clinical and genetic factors involved in Porto-sinusoidal vascular disorder after oxaliplatin exposure

    Digestive and Liver Disease, Vol. 56, Núm. 10, pp. 1721-1729

  2. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD

    Journal of Hepatology, Vol. 81, Núm. 5, pp. 827-836

  3. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 12, pp. 1604-1615

  4. Multidrug-resistant bacterial infections after liver transplantation: Prevalence, impact, and risk factors

    Journal of Hepatology, Vol. 80, Núm. 6, pp. 904-912

  5. One-step non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis and fibrosis in high-risk population

    United European Gastroenterology Journal, Vol. 12, Núm. 7, pp. 919-929

  6. Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome

    Journal of Hepatology

  7. Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study

    The Lancet Gastroenterology and Hepatology

  8. Strategic analysis and recommendations of the Sociedad Española de Patología Digestiva (SEPD) regarding population-based screening programs for colorectal cancer in Spain

    Revista espanola de enfermedades digestivas, Vol. 116, Núm. 6, pp. 319-329

  9. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

  10. Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU

    Digestive and Liver Disease